- Home
- DGLY vs DRMA Comparison
DGLY vs DRMA Comparison
Compare DGLY & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGLY
- DRMA
- Stock Information
- Founded
- DGLY N/A
- DRMA 2014
- Country
- DGLY United States
- DRMA United States
- Employees
- DGLY N/A
- DRMA N/A
- Industry
- DGLY Radio And Television Broadcasting And Communications Equipment
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- DGLY Technology
- DRMA Health Care
- Exchange
- DGLY Nasdaq
- DRMA Nasdaq
- Market Cap
- DGLY 4.1M
- DRMA 4.5M
- IPO Year
- DGLY N/A
- DRMA 2021
- Fundamental
- Price
- DGLY $2.30
- DRMA $0.66
- Analyst Decision
- DGLY
- DRMA Strong Buy
- Analyst Count
- DGLY 0
- DRMA 1
- Target Price
- DGLY N/A
- DRMA $3.00
- AVG Volume (30 Days)
- DGLY 399.3K
- DRMA 87.1K
- Earning Date
- DGLY 08-15-2025
- DRMA 08-06-2025
- Dividend Yield
- DGLY N/A
- DRMA N/A
- EPS Growth
- DGLY N/A
- DRMA N/A
- EPS
- DGLY N/A
- DRMA N/A
- Revenue
- DGLY $18,596,715.00
- DRMA N/A
- Revenue This Year
- DGLY N/A
- DRMA N/A
- Revenue Next Year
- DGLY N/A
- DRMA N/A
- P/E Ratio
- DGLY N/A
- DRMA N/A
- Revenue Growth
- DGLY N/A
- DRMA N/A
- 52 Week Low
- DGLY $1.93
- DRMA $0.57
- 52 Week High
- DGLY $265.00
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- DGLY 25.16
- DRMA 45.46
- Support Level
- DGLY $2.16
- DRMA $0.59
- Resistance Level
- DGLY $2.48
- DRMA $0.63
- Average True Range (ATR)
- DGLY 0.17
- DRMA 0.04
- MACD
- DGLY 1.44
- DRMA 0.00
- Stochastic Oscillator
- DGLY 22.58
- DRMA 56.96
About DGLY Digital Ally Inc.
Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.